

Active and planned clinical trials

Click **row** or **phase bar** to view clinical trial study designs in the indicated research area.

The safety and efficacy of investigational agents have not been established, and they have not received marketing authorization in this setting. There is no guarantee that investigational agents and/or uses will receive Health Authority approval and/or become commercially available.

Our scientific focus areas target:

- Tumour-intrinsic cell death
- Immune-mediated tumour/cell killing
- Tumour-permissive microenvironment

Oncology

RESEARCH AREA	MOLECULE(S)	PHASE 1	PHASE 2	PHASE 3
HEMATOLOGICAL MALIGNANCIES	1L high-risk LBCL (ZUMA-23)	Axicabtagene ciloleucel	NCT05605899	
	R/R DLBCL	KITE-197 (next-gen CD19 CAR-T)	NCT06079164	
	R/R DLBCL	KITE-363 (CD19/20 bicistronic)	NCT04989803	
	R/R DLBCL	KITE-753 (CD19/20 bicistronic)	NCT04989803	
	2L+ high-risk FL (ZUMA-22)	Axicabtagene ciloleucel	NCT05371093	
	R/R Pediatric ALL/NHL (ZUMA-4)	Brexucabtagene autoleucel	NCT02625480	
	R/R MM (iMMagine-3) ^a	Anitocabtagene autoleucel	NCT06413498	
	R/R MM (iMMagine-1) ^a	Anitocabtagene autoleucel	NCT05396885	
	R/R MM (Phase 1) ^a	Anitocabtagene autoleucel	NCT04155749	
BREAST	1L mTNBC, PD-L1- (ASCENT-03)	Sacituzumab govitecan (SG)	NCT05382299	
	1L mTNBC, PD-L1+ (ASCENT-04) ^b	Sacituzumab govitecan + pembro	NCT05382286	
	Adjuvant TNBC (ASCENT-05) ^c	Sacituzumab govitecan + pembro	NCT05633654	
	HR+/HER2- chemo-naïve mBC (ASCENT-07)	Sacituzumab govitecan	NCT05840211	
THORACIC	1L mNSCLC, PD-L1 TPS≥50% (EVOKE-03) ^b	Sacituzumab govitecan + pembro	NCT05609968	
	2L ES-SCLC (EVOKE-SCLC-04)	Sacituzumab govitecan	NCT05502237	
	1L mNSCLC, PD-L1 all comers (STAR-121) ^d	Domvanalimab + zimberelimab + chemo	NCT05186974	
	1L mNSCLC (EVOKE-02) ^b	Sacituzumab govitecan + pembro ± chemo	NCT04262856	
	Stage 2-3 resectable NSCLC, 1-2L mNSCLC (VELOCITY-Lung) ^e	Zim ± dom ± etruma ± chemo/SG combinations	NCT05633667	
	1L/2L+ mNSCLC (EDGE-Lung) ^d	Zim ± dom ± quemli ± chemo combinations	NCT06801834	
	1L r/m HNSCC, PD-L1 all comers (VELOCITY-HNSCC) ^d	Zimberelimab + chemotherapy ± domvanalimab	NCT06727565	
GU	1L/2L+ mUC (TROPHY U-01, multicohort)	Sacituzumab govitecan + combinations	NCT03547973	
GI	1L upper GI (STAR-221) ^{d,e}	Domvanalimab + zimberelimab + chemotherapy	NCT05568095	
	1L/2L+ upper GI (EDGE-Gastric) ^{d,f}	Dom + zim ± quemli + chemo combinations	NCT05329766	
	2L+ mCRC (ARC-9) ^{d,g}	Etruma + zim + chemo ± bev combinations	NCT04660812	1b/2
	1-2L mPDAC (ARC-8) ^{d,h}	Zimberelimab ± quemliclustat + chemotherapy	NCT04104672	
GYN	2L+ mEC (ASCENT-GYN-01) ⁱ	Sacituzumab govitecan	NCT06486441	
OTHER SOLID TUMOURS	Solid tumours (EVER-132-003)	Sacituzumab govitecan	NCT05119907	
	Solid tumour basket study (TROPICS-03) ^j	Sacituzumab govitecan	NCT03964727	
	Solid tumours	GS-9716 (MCL-1) + chemo or SG	NCT05006794	
	Solid tumours	GS-1811 (CCR8) ± zim	NCT05007782	
	Solid tumours	GS-4528 (IL-2 variant) ± zim	NCT05840224	
	Solid tumours	GS-0201 (PARP1) ± SG	NCT06167317	
	Solid tumours	GS-9911 (DGKα) ± zim	NCT06082960	
	Solid tumours	GS-2121 (undisclosed MoA) ± zim	NCT06532565	
	Solid tumours ^k	GS-0321 (IL18BP) ± zim	NCT06759649	
	Solid tumours ^l	XTX301 (IL-12)	NCT05684965	
	Glioblastoma ^m	CAR-T EGFR IL13Ra2	NCT05168423	
	Neuroblastoma ⁿ	CAR-T GPC2	NCT05650749	

Non-oncology

AD	Multiple indications	KITE-363 (CD19/20 bicistronic)	Preclinical
----	----------------------	--------------------------------	-------------

Multiple targets

Optionable Partner Programs^o

<div></div> Arcus: 2 clinical stage programs: Advanced Cancers	<div></div> MacroGenics: 1 clinical stage program: Advanced cancers
--	---

Targets

GS-9716	GS-0201	SG	Anito-cel	Axi-cel, Brexu-cel	KITE-197	KITE-363, KITE-753	GS-9911	GS-4528	XTX301	Zim	Dom	EGFR IL13Ra2 CAR-T	GPC2 CAR-T	Etruma	Quemli	GS-1811	GS-2121	GS-0321
MCL-1	PARP1	Trop-2	BCMA	CD19	CD19 Next-gen CAR-T	CD19/20 bicistronic	DGKα	IL-2 variant	IL-12	PD-1	TIGIT	EGFR IL13Ra2	GPC2	A2aR/A2bR	CD73	CCR8	undisclosed MoA	IL18BP

^aIn collaboration with Arcellx, Inc. ^bIn collaboration with Merck Sharp & Dohme. ^cIn collaboration with Alliance Foundation Trials, LLC and National Surgical Adjuvant Breast and Bowel Project Foundation, Inc. ^dIn collaboration with Arcus Biosciences. ^eSTAR-221: dom + zim + FOLFOX/CAPOX vs nivo + FOLFOX/CAPOX. ^fEDGE-Gastric: (1L) dom + zim + FOLFOX, zim + FOLFOX and (2L) dom + zim, zim + quemli. ^gARC-9: etruma + zim + FOLFOX vs FOLFOX ± bevacizumab, etruma + zim + FOLFOX ± bevacizumab vs rego, and etruma + zim + quemli. ^hARC-8: quemli + zim + gem/nab-pac. ⁱIn collaboration with the Gynecologic Oncology Group (GOG) Foundation, the European Network of Gynaecological Oncological Trial Groups (ENGOT) and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). ^jTROPICS-03: mNSCLC, mSCLC, mHNSCC, mEC. ^kOperationalized by Compugen. Also referred to as COM503. ^lOperationalized by Xilio Development, Inc. ^mIn collaboration with University of Pennsylvania. ⁿIn collaboration with Children's Hospital of Philadelphia. ^oOptionable Partner Programs: Selected programs listed are optionable partner programs. Gilead has not opted into these programs unless otherwise noted.

1L, first line; **2L**, second line; **A_{2a}R/A_{2b}R**, adenosine 2A receptor/adenosine 2B receptor; **AD**, autoimmune diseases; **ALL**, acute lymphoblastic leukemia; **BC**, breast cancer; **BCMA**, B-cell maturation antigen; **Bev**, bevacizumab; **CAPOX**, capecitabine + oxaliplatin; **CAR**, chimeric antigen receptor; **CCR8**, chemokine receptor 8; **CD19/20**, cluster of differentiation 19/20; **Chemo**, chemotherapy; **CRC**, colorectal cancer; **DGKα**, diacylglycerol kinase alpha; **DLBCL**, diffuse large B-cell lymphoma; **Dom**, domvanalimab; **EC**, endometrial cancer; **EGFR**, epidermal growth factor receptor; **ES-SCLC**, extensive-stage small cell lung cancer; **Etruma**, etrumadenant; **FL**, follicular lymphoma; **FOLFOX**, FOLinic acid, Fluorouracil and OXaliplatin; gem/nab-pac, gemcitabine/nab-paclitaxel; **Gem/Nab-pac**, gemcitabine/nab-paclitaxel; **GI**, gastrointestinal; **GPC2**, Glypican 2; **GU**, genitourinary; **GYN**, gynecological; **HER2**, human epidermal growth factor receptor 2; **HNSCC**, head and neck squamous cell carcinoma; **HR**, hormone receptor; **IL-2/12**, interleukin-2/12; **IL13Ra2**, interleukin-13 receptor subunit alpha 2; **IL18P**, interleukin-18 binding protein; **LBCL**, large B-cell lymphoma; **m**, metastatic; **MCL-1**, myeloid cell leukemia-1; **MM**, multiple myeloma; **MoA**, mechanism of action; **NCT**, national clinical trial; **NHL**, non-Hodgkin lymphoma; **Nivo**, nivolumab; **NSCLC**, non-small cell lung cancer; **PARP1**, poly adenosine diphosphate (ADP) ribose polymerase 1; **PD-(L)1**, programmed cell death (ligand) 1; **PDAC**, pancreatic ductal adenocarcinoma; **Pembro**, pembrolizumab; **Quemli**, quemliclustat; **Rego**, regorafenib; **r/m**, recurrent/metastatic; **R/R**, relapsed/refractory; **SCLC**, small cell lung cancer; **SG**, sacituzumab govitecan; **TIGIT**, T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains; **TNBC**, triple-negative breast cancer; **TPS**, tumour proportion score; **Trop-2**, trophoblast cell surface antigen 2; **UC**, urothelial cancer; **Zim**, zimberelimab.